Skip to content

TCRX - TScan Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchT

Tscan Therapeutics Inc

TCRX · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

T

TCRXTscan Therapeutics Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $2.57
52-wk low: $0.72
Prev close: $1.54
Mkt cap: $50.8M
Beta: 1.07
P/S: 7.2x

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$7.7M

TS
Two Sigma
Q2 2026 13F
$1.9M
position
JS
Jim Simons
Q2 2026 13F

Earnings

Reported Aug 11, 2026

Earnings came in 20.7% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $51M

Valuation

P/S7.15
P/B0.81

Quality

Operating margin-2901.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: TCRX
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $50.83M
Beta: 1.07

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/B

0.8x

Profit margin

+0.0%

Op margin

-2901.0%

ROE

-95.8%

$1.3M

position

MI

Millennium

Israel Englander · Q2 2026 13F

$1.1M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for TCRX

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.23+20.7%

-$0.29 expected

Next report

What the street expects next

-95.8%

ROA-31.5%

Growth

Beta1.07